BRIEF-J&J Says New Talvey Plus Darzalex Faspro Data Demonstrate Strength Of Bispecific Combination In Earlier-Line Relapsed Or Refractory Multiple Myeloma

Johnson & Johnson

Johnson & Johnson

JNJ

0.00

June 13 (Reuters) - Johnson & Johnson JNJ.N:

  • NEW TALVEY® (TALQUETAMAB-TGVS) PLUS DARZALEX FASPRO® (DARATUMUMAB AND HYALURONIDASE-FIHJ) DATA DEMONSTRATE THE STRENGTH OF A BISPECIFIC COMBINATION IN EARLIER-LINE RELAPSED OR REFRACTORY MULTIPLE MYELOMA

  • JJ - SUBMITS SBLA TO FDA AND TYPE II VARIATION TO EMA FOR TALVEY COMBINATION

  • JJ - TALVEY PLUS DARZALEX FASPRO SHOWS CONSISTENT SAFETY PROFILE AND REDUCED SEVERE INFECTIONS

  • JJ - TALVEY PLUS DARZALEX FASPRO OUTPERFORMS STANDARD OF CARE IN PFS AND OS AT 24 MONTHS

Source text: ID:nPn3WhtRJa

Further company coverage: JNJ.N


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.